ES3040563T3 - Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use - Google Patents

Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Info

Publication number
ES3040563T3
ES3040563T3 ES18723094T ES18723094T ES3040563T3 ES 3040563 T3 ES3040563 T3 ES 3040563T3 ES 18723094 T ES18723094 T ES 18723094T ES 18723094 T ES18723094 T ES 18723094T ES 3040563 T3 ES3040563 T3 ES 3040563T3
Authority
ES
Spain
Prior art keywords
seq
nanostructure
polypeptides
cav1
paramyxovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18723094T
Other languages
English (en)
Spanish (es)
Inventor
Neil King
David Baker
Brooke Nickerson
Lance Stewart
Laurent Perez
Antonio Lanzavecchia
Jessica Marcandalli
Jorge Fallas
Yang Hsia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inst Res Biomedicine
Institute for Research in Biomedicine IRB
University of Washington
Original Assignee
Inst Res Biomedicine
Institute for Research in Biomedicine IRB
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Res Biomedicine, Institute for Research in Biomedicine IRB, University of Washington filed Critical Inst Res Biomedicine
Application granted granted Critical
Publication of ES3040563T3 publication Critical patent/ES3040563T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nanotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES18723094T 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use Active ES3040563T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762481331P 2017-04-04 2017-04-04
PCT/US2018/025880 WO2018187325A1 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Publications (1)

Publication Number Publication Date
ES3040563T3 true ES3040563T3 (en) 2025-11-03

Family

ID=62116943

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18723094T Active ES3040563T3 (en) 2017-04-04 2018-04-03 Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use

Country Status (24)

Country Link
US (4) US11192926B2 (https=)
EP (2) EP4559869A3 (https=)
JP (3) JP7168938B2 (https=)
KR (2) KR102774312B1 (https=)
CN (3) CN115779077A (https=)
AU (3) AU2018249533C1 (https=)
BR (1) BR112019020661A2 (https=)
CA (1) CA3058794A1 (https=)
DK (1) DK3606942T3 (https=)
ES (1) ES3040563T3 (https=)
FI (1) FI3606942T3 (https=)
HR (1) HRP20251060T1 (https=)
HU (1) HUE073526T2 (https=)
IL (2) IL322023A (https=)
LT (1) LT3606942T (https=)
MX (2) MX2019011869A (https=)
PH (1) PH12019502276A1 (https=)
PL (1) PL3606942T3 (https=)
PT (1) PT3606942T (https=)
RS (1) RS67190B1 (https=)
SG (1) SG11201908999QA (https=)
SI (1) SI3606942T1 (https=)
SM (1) SMT202500317T1 (https=)
WO (1) WO2018187325A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9630994B2 (en) * 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
HUE073526T2 (hu) * 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
EP3746090A4 (en) 2018-01-29 2021-11-17 ModernaTX, Inc. RSV RNA Vaccines
WO2019169120A1 (en) 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines
CN113423718A (zh) 2019-02-08 2021-09-21 美国政府(由卫生和人类服务部的部长所代表) 基于纳米颗粒的流感病毒疫苗及其用途
EP4025587A1 (en) * 2019-09-04 2022-07-13 University of Washington Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN110878128A (zh) * 2019-11-04 2020-03-13 中国疾病预防控制中心病毒病预防控制所 一种人呼吸道合胞病毒粘膜疫苗及其制备方法和应用
JP2023513073A (ja) * 2020-01-30 2023-03-30 モデルナティエックス インコーポレイテッド 呼吸器系ウイルス免疫化組成物
PE20230486A1 (es) * 2020-02-14 2023-03-21 Univ Washington Polipeptidos y sus usos
WO2021163438A1 (en) * 2020-02-14 2021-08-19 University Of Washington Polypeptides, compositions, and their use to treat or limit development of an infection
KR20230044394A (ko) * 2020-06-09 2023-04-04 아이코사백스, 인크. 바이러스 유사 입자를 제조하는 방법
MX2022015593A (es) * 2020-06-09 2023-04-03 Icosavax Inc Metodo de ensamblaje de particulas similares a virus de dos componentes.
KR102860080B1 (ko) 2020-10-09 2025-09-15 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 융합전-안정화된 hmpv f 단백질
CN111991556B (zh) * 2020-10-29 2021-03-02 中山大学 SARS-CoV-2 RBD共轭纳米颗粒疫苗
AU2021380755A1 (en) 2020-11-13 2023-06-22 Icosavax, Inc. Protein-based nanoparticle vaccine for metapneumovirus
CN112778404B (zh) * 2021-01-28 2022-11-29 中山大学 一种含EB病毒gHgL蛋白的自组装纳米颗粒及其制备方法与应用
IL310628A (en) * 2021-08-10 2024-04-01 Icosavax Inc Virus-like particle vaccine for respiratory syncytial virus
KR20250025527A (ko) 2022-05-17 2025-02-21 아이코사백스, 인크. 파라믹소바이러스용 다가 백신 및 이의 용도
WO2024118544A2 (en) * 2022-11-29 2024-06-06 The Scripps Research Institute Vaccines containing novel nanoparticle scaffolds
WO2024131862A1 (zh) * 2022-12-22 2024-06-27 北京吉诺卫生物科技有限公司 一种rsv疫苗及其制备方法与应用
CN118108812B (zh) * 2023-05-04 2025-04-15 国药中生生物技术研究院有限公司 Rsv f蛋白的突变体
IL325774A (en) * 2023-07-18 2026-03-01 Astrazeneca Ab RSV vaccine
CN119930762A (zh) * 2023-11-03 2025-05-06 广东蓝玉生物科技有限公司 非洲猪瘟病毒ep153r蛋白的免疫原性组合物及其应用
CN121758570A (zh) * 2023-11-03 2026-03-31 广东蓝玉生物科技有限公司 非洲猪瘟病毒CD2v蛋白的免疫原性组合物及其应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4238904A1 (de) 1992-11-19 1994-05-26 Basf Ag Riboflavin-Synthese in Hefen
US6262202B1 (en) 1998-03-04 2001-07-17 Univation Technologies, Llc Noncoordinating anions for olefin polymerization
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
JP2000152791A (ja) 1998-11-11 2000-06-06 E I Du Pont De Nemours & Co ルマジンシンターゼおよびリボフラビンシンターゼ
US20040005672A1 (en) 2002-02-22 2004-01-08 Santi Daniel V. Heterologous production of polyketides
WO2004024744A2 (en) 2002-07-31 2004-03-25 The Board Of Trustees Of The Leland Stanford Junior University Production of glycosylated macrolides in e. coli
EP1773303A2 (en) 2004-05-25 2007-04-18 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
EP1793850A4 (en) 2004-09-21 2010-06-30 Medimmune Inc ANTIBODIES TO THE METHOD AND METHOD FOR THE PRODUCTION OF VACCINES AGAINST THE RESPIRATORY SYNCYTIAL VIRUS
JP5711972B2 (ja) 2007-12-24 2015-05-07 アイディー バイオメディカル コーポレイション オブ ケベック 組換えｒｓｖ抗原
US9102526B2 (en) 2008-08-12 2015-08-11 Imiplex Llc Node polypeptides for nanostructure assembly
WO2010019725A2 (en) 2008-08-12 2010-02-18 Salemme Francis R Node polypeptides for nanostructure assembly
GB0817507D0 (en) 2008-09-24 2008-10-29 Ucl Business Plc Protein cages
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
US20110200560A1 (en) 2009-05-26 2011-08-18 Massachusetts Institute Of Technology Non-ionic self-assembling peptides and uses thereof
WO2011017835A1 (en) 2009-08-11 2011-02-17 Nanjing University Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding
US8920812B2 (en) 2009-11-03 2014-12-30 Takeda Vaccines, Inc. Chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus Gag-based VLPS
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
CN103282378B (zh) * 2010-10-06 2015-03-11 华盛顿大学商业中心 多肽及其在治疗和限制呼吸道合胞病毒感染中的用途
CA2835644C (en) 2011-05-13 2021-06-15 Novartis Ag Pre-fusion rsv f antigens
EP2758038B1 (en) 2011-09-23 2018-05-30 The United States of America, as represented by The Secretary, Department of Health & Human Services Novel influenza hemagglutinin protein-based vaccines
RU2014117068A (ru) 2011-09-30 2015-11-10 Новавакс, Инк. Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса
WO2013056122A1 (en) 2011-10-12 2013-04-18 University Of Washington Engineered outer domain (eod) of hv gp120 and mutants thereof
HK1210479A1 (en) 2012-04-10 2016-04-22 The Trustees Of The University Of Pennsylvania Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same
US8969521B2 (en) 2012-04-11 2015-03-03 University Of Washington Through Its Center For Commercialization General method for designing self-assembling protein nanomaterials
WO2014005643A1 (en) 2012-07-05 2014-01-09 Okairos Ag Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
CA2878344A1 (en) 2012-07-06 2014-01-09 Novartis Ag Complexes of cytomegalovirus proteins
KR102435054B1 (ko) 2012-08-01 2022-08-22 버베리안 노딕 에이/에스 재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
US20140141037A1 (en) 2012-11-20 2014-05-22 Novartis Ag Rsv f prefusion trimers
EP2922570A1 (en) 2012-11-20 2015-09-30 GlaxoSmithKline Biologicals SA Rsv f prefusion trimers
US10248758B2 (en) 2013-02-07 2019-04-02 University Of Washington Through Its Center For Commercialization Self-assembling protein nanostructures
US9738689B2 (en) 2013-03-13 2017-08-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion RSV F proteins and their use
EP2970398B1 (en) * 2013-03-13 2024-05-08 The United States of America, as Represented by The Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
US9060975B2 (en) 2013-03-14 2015-06-23 Mucosis Bv Heat-stable respiratory syncytial virus F protein oligomers and their use in immunological compositions
EP2975052B1 (en) * 2013-03-15 2020-09-23 Xiamen University Epitope of rsv fusion protein and antibody identifying same
KR102236497B1 (ko) 2013-04-25 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 안정화된 가용성 예비융합 ｒｓｖ ｆ 폴리펩타이드
CN105408348B (zh) 2013-06-17 2021-07-06 扬森疫苗与预防公司 稳定化的可溶性融合前rsv f多肽
CN104436202B (zh) 2013-09-12 2017-07-28 中国科学院深圳先进技术研究院 聚合物纳米颗粒、其制备方法及疫苗组合物、疫苗制剂及其制备方法
JP2016533332A (ja) * 2013-09-24 2016-10-27 マサチューセッツ インスティテュート オブ テクノロジー 自己集合型ナノ粒子ワクチン
US20150166610A1 (en) 2013-10-14 2015-06-18 Glaxosmithkline Biologicals, S.A. Recombinant rsv antigens
JP6652500B2 (ja) 2014-01-09 2020-02-26 アルファ−オ ペプティデス アクツィエンゲゼルシャフト ワクチンプラットフォームとしてのフラジェリン含有タンパク質ナノ粒子
EP2974739A1 (en) * 2014-07-15 2016-01-20 Novartis AG RSVF trimerization domains
EA035375B1 (ru) 2014-07-10 2020-06-03 Янссен Вэксинс Энд Превеншн Б.В. Вакцины против вируса гриппа и их применения
US9630994B2 (en) 2014-11-03 2017-04-25 University Of Washington Polypeptides for use in self-assembling protein nanostructures
US11191727B2 (en) 2014-12-31 2021-12-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multivalent nanoparticle-based vaccines
WO2016138525A1 (en) 2015-02-27 2016-09-01 University Of Washington Polypeptide assemblies and methods for the production thereof
WO2016160166A1 (en) 2015-03-30 2016-10-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic rsv polypeptides
EA039065B1 (ru) 2015-07-07 2021-11-29 Янссен Вэксинс Энд Превеншн Б.В. Вакцина против rsv
US10457708B2 (en) 2015-07-07 2019-10-29 Janssen Vaccines & Prevention B.V. Stabilized soluble pre-fusion RSV F polypeptides
WO2017027480A1 (en) 2015-08-13 2017-02-16 Echogen Power Systems, L.L.C. Heat engine system including an integrated cooling circuit
CA2996762A1 (en) 2015-08-31 2017-03-09 Technovax, Inc. Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
CA2996007A1 (en) 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
US10688175B2 (en) 2015-10-13 2020-06-23 Daniel C. Carter NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
MX2018005462A (es) 2015-10-29 2018-08-01 Univ Emory Composiciones inmunogénicas de rsv quimérico y métodos de uso.
RU2723039C2 (ru) 2015-12-23 2020-06-08 Пфайзер Инк. Мутанты белка f rsv
WO2017172890A1 (en) 2016-03-29 2017-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Substitutions-modified prefusion rsv f proteins and their use
IL262108B2 (en) 2016-04-05 2023-04-01 Janssen Vaccines Prevention B V Soluble pre-fusion rsv f proteins are stabilized
CN109311946A (zh) 2016-05-30 2019-02-05 扬森疫苗与预防公司 稳定化的融合前rsv f蛋白
WO2017207477A1 (en) 2016-05-30 2017-12-07 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion rsv f proteins
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
US11084850B2 (en) 2016-12-16 2021-08-10 The Pirbright Institute Recombinant prefusion RSV F proteins and uses thereof
HUE073526T2 (hu) 2017-04-04 2026-01-28 Univ Washington Önmagát összeállító fehérje nanostruktúrák, amelyek paramyxovírus és/vagy pneumovírus F fehérjéket jelenítenek meg és azok használata
CN107157933B (zh) 2017-05-04 2021-05-11 同济大学 一种蛋白自组装新型纳米疫苗及其制备方法
WO2019169120A1 (en) * 2018-02-28 2019-09-06 University Of Washington Self-asssembling nanostructure vaccines

Also Published As

Publication number Publication date
CA3058794A1 (en) 2018-10-11
JP7168938B2 (ja) 2022-11-10
SMT202500317T1 (it) 2025-11-10
SI3606942T1 (sl) 2025-11-28
CN115947873A (zh) 2023-04-11
WO2018187325A1 (en) 2018-10-11
EP4559869A2 (en) 2025-05-28
US20220169681A1 (en) 2022-06-02
JP2024160321A (ja) 2024-11-13
EP3606942B1 (en) 2025-06-11
CN110603262A (zh) 2019-12-20
KR102774312B1 (ko) 2025-03-05
EP3606942A1 (en) 2020-02-12
US20250263445A1 (en) 2025-08-21
US20200392187A1 (en) 2020-12-17
BR112019020661A2 (pt) 2020-05-05
PT3606942T (pt) 2025-09-01
PL3606942T3 (pl) 2025-11-12
FI3606942T3 (fi) 2025-08-29
AU2018249533C1 (en) 2023-10-12
JP2020515280A (ja) 2020-05-28
HUE073526T2 (hu) 2026-01-28
IL269643A (en) 2019-11-28
RU2019130167A3 (https=) 2021-12-22
IL322023A (en) 2025-09-01
AU2018249533A1 (en) 2019-10-17
PH12019502276A1 (en) 2020-09-28
KR20240161683A (ko) 2024-11-12
JP2023002680A (ja) 2023-01-10
MX2023004704A (es) 2023-05-09
US11192926B2 (en) 2021-12-07
CN115779077A (zh) 2023-03-14
AU2024220089A1 (en) 2024-10-17
EP4559869A3 (en) 2025-08-20
LT3606942T (lt) 2025-10-10
HRP20251060T1 (hr) 2025-11-07
US12275757B2 (en) 2025-04-15
MX2019011869A (es) 2020-01-09
US11732011B2 (en) 2023-08-22
AU2022202787A1 (en) 2022-05-19
AU2018249533B2 (en) 2022-01-27
RS67190B1 (sr) 2025-10-31
US20240150411A1 (en) 2024-05-09
KR20190140916A (ko) 2019-12-20
RU2019130167A (ru) 2021-05-05
SG11201908999QA (en) 2019-10-30
AU2022202787C1 (en) 2025-01-30
JP7541701B2 (ja) 2024-08-29
DK3606942T3 (da) 2025-09-08
AU2022202787B2 (en) 2024-07-04

Similar Documents

Publication Publication Date Title
ES3040563T3 (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
CN112088014B (zh) 自组装纳米结构疫苗
ES3058501T3 (en) Rsv f protein mutants
TWI663175B (zh) 穩定化可溶性融合前ｒｓｖ ｆ多肽
JP2025172875A (ja) パラミクソウイルスおよび／またはニューモウイルスのｆタンパク質を提示する自己組織化タンパク質ナノ構造体ならびにその使用
RU2844177C2 (ru) Самосборные белковые наноструктуры, экспонирующие f-белки парамиксовируса и/или пневмовируса, и их применение
HK40128177A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
HK40014567A (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
HK40014567B (en) Self-assembling protein nanostructures displaying paramyxovirus and/or pneumovirus f proteins and their use
KR20260010717A (ko) 코로나바이러스 스파이크 당단백질 수용체 결합 도메인 및 이의 용도
WO2013152169A1 (en) Polypeptides and their use in treating metapneumovirus (mpv) infection